US4288627A
(en)
|
1980-02-12 |
1981-09-08 |
Phillips Petroleum Company |
Oxidation of thiols employing cobalt molybdate/triethylamine catalyst
|
NZ202757A
(en)
|
1981-12-23 |
1985-11-08 |
Novo Industri As |
Peptides and medicaments
|
US5614492A
(en)
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
US5118666A
(en)
|
1986-05-05 |
1992-06-02 |
The General Hospital Corporation |
Insulinotropic hormone
|
US5120712A
(en)
|
1986-05-05 |
1992-06-09 |
The General Hospital Corporation |
Insulinotropic hormone
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
ES2113879T3
(es)
|
1990-01-24 |
1998-05-16 |
Douglas I Buckley |
Analogos de glp-1 utiles para el tratamiento de diabetes.
|
KR100237148B1
(ko)
|
1990-05-09 |
2000-01-15 |
한센 핀 베네드 |
엔도글루칸아제 효소를 함유하는 셀룰라제 제조물
|
DK36392D0
(da)
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Anvendelse af kemisk forbindelse
|
US5846747A
(en)
|
1992-03-25 |
1998-12-08 |
Novo Nordisk A/S |
Method for detecting glucagon-like peptide-1 antagonists and agonists
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
AU7531094A
(en)
|
1993-08-24 |
1995-03-21 |
Novo Nordisk A/S |
Protracted glp-1
|
DE69426304T2
(de)
|
1993-09-07 |
2001-03-15 |
Amylin Pharmaceuticals, Inc. |
Methoden zur regulation der den magen und darm betreffenden motilitaet
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
US5523449A
(en)
|
1995-05-17 |
1996-06-04 |
Bayer Corporation |
Process for preparing phosphorodichlorido-dithioates by reacting alkylmercaptans with phosphorus trichloride in the presence of sulfur
|
AU723694B2
(en)
|
1996-06-05 |
2000-08-31 |
Roche Diagnostics Gmbh |
Exendin analogues, processes for their preparation and medicaments containing them
|
US6110703A
(en)
|
1996-07-05 |
2000-08-29 |
Novo Nordisk A/S |
Method for the production of polypeptides
|
DE69739172D1
(de)
|
1996-08-08 |
2009-01-29 |
Amylin Pharmaceuticals Inc |
Regulation gastrointestinaler beweglichkeit
|
RU2214419C2
(ru)
|
1996-08-30 |
2003-10-20 |
Ново Нордиск А/С |
Glp-1 производные
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6277819B1
(en)
|
1996-08-30 |
2001-08-21 |
Eli Lilly And Company |
Use of GLP-1 or analogs in treatment of myocardial infarction
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6006753A
(en)
|
1996-08-30 |
1999-12-28 |
Eli Lilly And Company |
Use of GLP-1 or analogs to abolish catabolic changes after surgery
|
US6384016B1
(en)
|
1998-03-13 |
2002-05-07 |
Novo Nordisk A/S |
Stabilized aqueous peptide solutions
|
AU724326B2
(en)
|
1996-09-09 |
2000-09-14 |
Zealand Pharmaceuticals A/S |
Peptide prodrugs containing an alpha-hydroxyacid linker
|
ES2239364T3
(es)
|
1996-09-09 |
2005-09-16 |
Zealand Pharma A/S |
Sintesis de peptidos en fase solida.
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
WO1998022577A1
(en)
|
1996-11-15 |
1998-05-28 |
Maria Grazia Masucci |
Fusion proteins having increased half-lives
|
WO1998030231A1
(en)
|
1997-01-07 |
1998-07-16 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the reduction of food intake
|
US6136784A
(en)
|
1997-01-08 |
2000-10-24 |
Amylin Pharmaceuticals, Inc. |
Amylin agonist pharmaceutical compositions containing insulin
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
WO1998035033A1
(en)
|
1997-02-05 |
1998-08-13 |
1149336 Ontario Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
US5846937A
(en)
|
1997-03-03 |
1998-12-08 |
1149336 Ontario Inc. |
Method of using exendin and GLP-1 to affect the central nervous system
|
WO1998050351A1
(en)
|
1997-05-07 |
1998-11-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin |
New cysteine derivatives, processes for their production, and pharmaceuticals containing them
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
EP1019077B2
(en)
|
1997-08-08 |
2010-12-22 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
DE69838916T2
(de)
|
1997-11-14 |
2008-12-18 |
Amylin Pharmaceuticals, Inc., San Diego |
Neuartige exendin agonisten
|
AU756836B2
(en)
|
1997-11-14 |
2003-01-23 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
JP2001525371A
(ja)
|
1997-12-05 |
2001-12-11 |
イーライ・リリー・アンド・カンパニー |
Glp−1製剤
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
JP4677095B2
(ja)
|
1998-02-13 |
2011-04-27 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
エキセンジンおよびglp−1の変力および利尿効果
|
EP1056775B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
DE69942307D1
(de)
|
1998-02-27 |
2010-06-10 |
Novo Nordisk As |
N-terminal veränderte glp-1 abkömmlinge
|
EP1950224A3
(en)
|
1998-03-09 |
2008-12-17 |
Zealand Pharma A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
WO1999049788A1
(en)
|
1998-03-30 |
1999-10-07 |
Focus Surgery, Inc. |
Ablation system
|
SE9802080D0
(sv)
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
WO2000009666A2
(en)
|
1998-08-10 |
2000-02-24 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof
|
EP1119625B1
(en)
|
1998-10-07 |
2005-06-29 |
Medical College Of Georgia Research Institute, Inc. |
Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
PL202367B1
(pl)
|
1998-12-07 |
2009-06-30 |
Sod Conseils Rech Applic |
Związki stanowiące analogi GLP-1, kompozycje zawierające te związki oraz zastosowanie tych związków
|
WO2000041546A2
(en)
|
1999-01-14 |
2000-07-20 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist formulations and methods of administration thereof
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
JP2002538084A
(ja)
|
1999-01-14 |
2002-11-12 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
グルカゴンを抑制する方法
|
US6451987B1
(en)
|
1999-03-15 |
2002-09-17 |
Novo Nordisk A/S |
Ion exchange chromatography of proteins and peptides
|
RU2001128068A
(ru)
|
1999-03-17 |
2004-02-20 |
Ново Нордиск А/С (DK) |
Способ ацилирования пептидов и новые ацилирующие агенты
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
US6271241B1
(en)
|
1999-04-02 |
2001-08-07 |
Neurogen Corporation |
Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
|
CN1372570A
(zh)
|
1999-04-30 |
2002-10-02 |
安米林药品公司 |
修饰的exendin和exendin激动剂
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
PT1180121E
(pt)
|
1999-05-17 |
2004-03-31 |
Conjuchem Inc |
Peptidos insulinotropicos de longa duracao
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
US6586438B2
(en)
|
1999-11-03 |
2003-07-01 |
Bristol-Myers Squibb Co. |
Antidiabetic formulation and method
|
WO2002034285A2
(en)
|
2000-10-20 |
2002-05-02 |
Coolidge Thomas R |
Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
|
GB0121709D0
(en)
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
AU2002346491A1
(en)
|
2001-12-19 |
2003-07-09 |
Eli Lilly And Company |
Crystalline compositions for controlling blood glucose
|
CA2468100A1
(en)
|
2001-12-20 |
2003-07-03 |
Eli Lilly And Company |
Insulin molecule having protracted time action
|
EP1525219B1
(en)
|
2002-07-04 |
2009-05-27 |
Zealand Pharma A/S |
Glp-1 and methods for treating diabetes
|
BR0314996A
(pt)
|
2002-10-02 |
2005-08-09 |
Zealand Pharma As |
Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
|
US7192922B2
(en)
|
2002-11-19 |
2007-03-20 |
Allegheny-Singer Research Institute |
Method of treating left ventricular dysfunction
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
EP1620465A2
(en)
|
2003-04-29 |
2006-02-01 |
Eli Lilly And Company |
Insulin analogs having protracted time action
|
KR101293507B1
(ko)
*
|
2003-06-03 |
2013-08-06 |
노보 노르디스크 에이/에스 |
안정화된 약학적 펩티드 조성물
|
US7623530B2
(en)
|
2003-11-20 |
2009-11-24 |
Nokia Corporation |
Indication of service flow termination by network control to policy decision function
|
CA2554458A1
(en)
|
2004-01-30 |
2005-08-11 |
Waratah Pharmaceuticals, Inc. |
The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
CN106137952B
(zh)
|
2004-11-12 |
2020-11-17 |
诺和诺德公司 |
促胰岛素肽的稳定制剂
|
TWI372629B
(en)
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
WO2006121860A2
(en)
|
2005-05-06 |
2006-11-16 |
Bayer Pharmaceuticals Corporation |
Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
|
KR101349808B1
(ko)
|
2005-06-13 |
2014-02-13 |
임페리얼 이노베이션스 리미티드 |
섭취행동에 관한 신규 화합물들 및 이들의 효능
|
US20090202497A1
(en)
|
2005-08-23 |
2009-08-13 |
The General Hospital Corporation |
Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
|
ES2507098T3
(es)
|
2005-11-07 |
2014-10-14 |
Indiana University Research And Technology Corporation |
Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
|
US8343914B2
(en)
|
2006-01-06 |
2013-01-01 |
Case Western Reserve University |
Fibrillation resistant proteins
|
WO2007095737A1
(en)
|
2006-02-21 |
2007-08-30 |
Waratah Pharmaceuticals Inc. |
Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound
|
CA2638800A1
(en)
|
2006-02-22 |
2007-09-07 |
Merck & Co., Inc. |
Oxyntomodulin derivatives
|
CA2658276A1
(en)
|
2006-07-18 |
2008-01-24 |
Sanofi-Aventis |
Antagonist antibody for the treatment of cancer
|
ITMI20061607A1
(it)
|
2006-08-09 |
2008-02-10 |
Maria Vincenza Carriero |
Peptidi con attivita farmacologica
|
ES2554773T3
(es)
|
2006-10-04 |
2015-12-23 |
Case Western Reserve University |
Insulina y análogos de la insulina resistentes a la fibrilación
|
AU2007319066B2
(en)
|
2006-11-08 |
2013-09-19 |
Zealand Pharma A/S |
Selective glucagon-like-peptide-2 (GLP-2) analogues
|
WO2008071010A1
(en)
|
2006-12-12 |
2008-06-19 |
Waratah Pharmaceuticals Inc. |
Combination treatments with selected growth/hormone regulatory factors for diabetes and related diseases
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
MX2009006564A
(es)
*
|
2007-01-05 |
2009-06-26 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon que muestran solubilidad potenciada en amortiguadores a ph fisiologico.
|
WO2008101017A2
(en)
|
2007-02-15 |
2008-08-21 |
Indiana Unversity Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
EP2025684A1
(en)
|
2007-08-15 |
2009-02-18 |
Zealand Pharma A/S |
Glucagon analogues
|
FR2917552B1
(fr)
|
2007-06-15 |
2009-08-28 |
Sagem Defense Securite |
Procede de regulation de la gigue de transmission au sein d'un terminal de reception
|
EP2158214B1
(en)
|
2007-06-15 |
2011-08-17 |
Zealand Pharma A/S |
Glucagon analogues
|
MX2010005317A
(es)
|
2007-11-20 |
2010-06-02 |
Ambrx Inc |
Polipeptidos de insulina modificados y sus usos.
|
GB2455553B
(en)
|
2007-12-14 |
2012-10-24 |
Nuaire Ltd |
Motor mounting assembly for an axial fan
|
DE102008003568A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DE102008003566A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
CN101970476B
(zh)
|
2008-01-09 |
2014-08-27 |
塞诺菲-安万特德国有限公司 |
具有超延迟时效特征的胰岛素衍生物
|
PL2229407T3
(pl)
|
2008-01-09 |
2017-06-30 |
Sanofi-Aventis Deutschland Gmbh |
Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
|
US8993516B2
(en)
|
2008-04-14 |
2015-03-31 |
Case Western Reserve University |
Meal-time insulin analogues of enhanced stability
|
RU2010147076A
(ru)
|
2008-04-22 |
2012-05-27 |
Кейз Вестерн Ризев Юнивесити (Us) |
Аналоги инсулина специфичные к изоформам
|
TWI451876B
(zh)
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
CA2727161A1
(en)
|
2008-06-17 |
2009-12-23 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
|
DK2300035T3
(en)
|
2008-06-17 |
2015-11-16 |
Univ Indiana Res & Tech Corp |
Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
|
WO2009155258A2
(en)
|
2008-06-17 |
2009-12-23 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
PL219335B1
(pl)
|
2008-07-04 |
2015-04-30 |
Inst Biotechnologii I Antybiotyków |
Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
|
BRPI0916560A2
(pt)
|
2008-07-31 |
2015-11-10 |
Univ Case Western Reserve |
análogo de insulina, ácido nucléico, vetor de expressão, célula hospedeira e método de tratamento de um paciente.
|
MX2011001031A
(es)
|
2008-08-07 |
2011-04-26 |
Ipsen Pharma Sas |
Analogos de polipeptidos insulinotropicos dependientes de glucosa.
|
JP5591243B2
(ja)
|
2008-09-12 |
2014-09-17 |
ノボ・ノルデイスク・エー/エス |
ペプチド又はタンパク質のアシル化の方法
|
WO2010070253A1
(en)
*
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
JP5635532B2
(ja)
*
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
AP2011005774A0
(en)
|
2008-12-15 |
2011-06-30 |
Zealand Pharma As |
Glucagon analogues.
|
CN102292347A
(zh)
|
2008-12-15 |
2011-12-21 |
西兰制药公司 |
胰高血糖素类似物
|
CA2747490C
(en)
|
2008-12-19 |
2017-02-14 |
Indiana University Research And Technology Corporation |
Insulin analogs
|
AU2009335715B2
(en)
|
2008-12-19 |
2016-09-15 |
Indiana University Research And Technology Corporation |
Amide-based insulin prodrugs
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
WO2010107487A2
(en)
|
2009-03-18 |
2010-09-23 |
Wu Nian |
Lipid-drug conjugates for drug delivery
|
CN101519446A
(zh)
|
2009-03-31 |
2009-09-02 |
上海一就生物医药有限公司 |
一种重组人胰岛素及其类似物的制备方法
|
KR20120005021A
(ko)
|
2009-05-08 |
2012-01-13 |
제넨테크, 인크. |
인간화 항-egfl7 항체 및 그의 사용 방법
|
US9150632B2
(en)
|
2009-06-16 |
2015-10-06 |
Indiana University Research And Technology Corporation |
GIP receptor-active glucagon compounds
|
GEP20146056B
(en)
*
|
2009-07-13 |
2014-03-10 |
Zealand Pharma As |
Acylated glucagon analogues
|
US20120329711A1
(en)
|
2009-12-16 |
2012-12-27 |
Nordisk A/S |
Glp-1 receptor agonist compounds with a modified n-terminus
|
WO2011084808A2
(en)
|
2009-12-21 |
2011-07-14 |
Amunix Operating Inc. |
Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
|
EP2525809B1
(en)
|
2010-01-20 |
2016-08-03 |
Zealand Pharma A/S |
Glucagon-glp1 dual agonists for use in the treatment of cardiac conditions
|
US8551946B2
(en)
|
2010-01-27 |
2013-10-08 |
Indiana University Research And Technology Corporation |
Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
|
AR080592A1
(es)
|
2010-03-26 |
2012-04-18 |
Lilly Co Eli |
Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
|
EP2552952A1
(en)
|
2010-03-26 |
2013-02-06 |
Novo Nordisk A/S |
Novel glucagon analogues
|
WO2011117415A1
(en)
|
2010-03-26 |
2011-09-29 |
Novo Nordisk A/S |
Novel glucagon analogues
|
EA023925B1
(ru)
|
2010-04-27 |
2016-07-29 |
Зилэнд Фарма А/С |
Пептидные конъюгаты агонистов рецептора glp-1 и их применение
|
EP2565205B1
(en)
|
2010-04-27 |
2015-07-01 |
Betta Pharmaceuticals Co., Ltd. |
Glucagon-like peptide-1 analogue and use thereof
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
NZ604208A
(en)
|
2010-06-24 |
2014-10-31 |
Zealand Pharma As |
Glucagon analogues
|
WO2011163473A1
(en)
*
|
2010-06-25 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
|
US9006178B2
(en)
|
2010-11-09 |
2015-04-14 |
Novo Nordisk A/S |
Double-acylated GLP-1 derivatives with a linker
|
WO2012098462A1
(en)
|
2011-01-20 |
2012-07-26 |
Zealand Pharma A/S |
Combination of acylated glucagon analogues with insulin analogues
|
US20140031278A1
(en)
|
2011-03-28 |
2014-01-30 |
Novo Nordisk A/S |
Novel Glucagon Analogues
|
PL2696687T3
(pl)
|
2011-04-12 |
2017-06-30 |
Novo Nordisk A/S |
Pochodne podwójnie acylowanej GLP-1
|
WO2012150503A2
(en)
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
WO2012153196A2
(en)
|
2011-05-10 |
2012-11-15 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
KR102002783B1
(ko)
|
2011-06-10 |
2019-07-24 |
베이징 한미 파마슈티컬 컴퍼니 리미티드 |
포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
|
AR088161A1
(es)
|
2011-09-23 |
2014-05-14 |
Novo Nordisk As |
Analogos de glucagon
|
AP2014007797A0
(en)
|
2011-12-23 |
2014-07-31 |
Boehringer Ingelheim Int |
Glucagon analogues
|
WO2013098408A1
(en)
*
|
2011-12-30 |
2013-07-04 |
Zealand Pharma A/S |
Glucagon and cck receptor agonist peptide conjugates
|
EA028929B1
(ru)
|
2012-05-03 |
2018-01-31 |
Зилэнд Фарма А/С |
Аналоги глюкагоноподобного пептида-2 (glp-2)
|
NZ702333A
(en)
|
2012-05-03 |
2017-06-30 |
Zealand Pharma As |
Gip-glp-1 dual agonist compounds and methods
|
WO2014016300A1
(en)
*
|
2012-07-23 |
2014-01-30 |
Zealand Pharma A/S |
Glucagon analogues
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
AR098065A1
(es)
|
2013-10-17 |
2016-04-27 |
Zealand Pharma As |
Análogos de glucagón acilados
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
MX2016005556A
(es)
|
2013-11-06 |
2016-07-15 |
Zealand Pharma As |
Compuestos agonistas duales de gip-glp-1 y procedimientos.
|
JP2017509603A
(ja)
|
2014-02-18 |
2017-04-06 |
ノヴォ ノルディスク アー/エス |
安定なグルカゴン類似体及び低血糖症の処置のための使用
|
DK3283507T3
(da)
|
2015-04-16 |
2020-01-02 |
Zealand Pharma As |
Acyleret glucagonanalog
|